ArticleAdvances in therapy2026
Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBased upon recent phase 3 trials, guidelines recommend early aggressive treatment for patients with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer. We assessed how this aligns with current real-world treatment patterns.
methodsDescriptive analyses were performed on data abstracted from an independent, retrospective, cross-sectional survey, which collected information regarding treatment from urologists and radiation oncologists in the USA between April and November 2023 who were managing patients with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer. Data were derived from physician responses to questions regarding their perspectives on treatment and patient record forms for their last 6-10 patients with high-risk biochemical recurrence. Although the survey was retrospective in nature and not based on a true random sample of physicians and patients, the relatively minimal inclusion criteria used attempted to ensure a broad representation of physicians and patients with high-risk biochemically recurrent prostate cancer.
resultsAn analysis cohort of 87 physicians submitted data for 535 eligible patients. Median time from diagnosis with high-risk biochemical recurrence to first-line treatment was 20 days. Median time between high-risk biochemical recurrence diagnosis and end of data collection was 286 days. The most common first-line treatments were androgen deprivation therapy alone (28%), radiation (20%), androgen receptor pathway inhibitor + androgen deprivation therapy (19%), and observation (13%). Among patients who received androgen deprivation therapy, 79% received it continuously. Adherence to treatment guidelines (cited by 49%) was the most common reason for physicians' first-line treatment choice.
conclusionsIn our real-world analysis, patients with high-risk biochemically recurrent prostate cancer rapidly received first-line treatment after diagnosis. The top reason for treatment choice was adherence to guidelines. Our finding that patients with biochemical recurrence are promptly treated in the real world aligns with guidance suggesting clinical benefit of early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.